STRIFON FORTE DSC

Post-LOE

chlorzoxazone

Ferndale Pharma Group

ANDAORALTABLET

Approved

Dec 1988

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

2/8 — Basic

STRIFON FORTE DSC (chlorzoxazone) by Ferndale Pharma Group is clinical pharmacology chlorzoxazone is a centrally-acting agent for painful musculoskeletal conditions. First approved in 1988.

Drug data last refreshed 19h ago

Mechanism of Action

CLINICAL PHARMACOLOGY Chlorzoxazone is a centrally-acting agent for painful musculoskeletal conditions. Data available from animal experiments as well as human study indicate that chlorzoxazone acts primarily at the level of the spinal cord and subcortical areas of the brain where it inhibits…

Indications

Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.

Company

Worked on STRIFON FORTE DSC at Ferndale Pharma Group? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.